Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2024)

Solid Biosciences (SLDB) has disclosed Income from Continuing Operations for 8 consecutive years, with 38046000.0 as the latest value for Q4 2024.

  • Quarterly Income from Continuing Operations fell 84.64% to 38046000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 120599000.0 through Dec 2024, down 24.19% year-over-year, with the annual reading at 169099000.0 for FY2025, 40.22% down from the prior year.
  • Income from Continuing Operations hit 38046000.0 in Q4 2024 for Solid Biosciences, down from 32936000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 16900000.0 in Q1 2021 to a low of 38046000.0 in Q4 2024.
  • Historically, Income from Continuing Operations has averaged 24105850.0 across 5 years, with a median of 22834500.0 in 2020.
  • Biggest five-year swings in Income from Continuing Operations: surged 37.62% in 2023 and later crashed 84.64% in 2024.
  • Year by year, Income from Continuing Operations stood at 21363000.0 in 2020, then grew by 12.69% to 18652000.0 in 2021, then tumbled by 77.1% to 33032000.0 in 2022, then soared by 37.62% to 20606000.0 in 2023, then plummeted by 84.64% to 38046000.0 in 2024.
  • Business Quant data shows Income from Continuing Operations for SLDB at 38046000.0 in Q4 2024, 32936000.0 in Q3 2024, and 25311000.0 in Q2 2024.